Asymmetric Oxidation of Sulphides Using Chiral Titanium Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing the enantiomerically enriched form of 5-(1H-pyrrol-1-yl)-2-[[(4-methoxy-3-methyl-2-pyridyl)-methyl]sulfinyl]-benzimidazole compounds have low enantioselectivity and poor yield, making them unsuitable for producing optically pure compounds effective for treating gastric acid-related disorders.
Innovation Solution
A process involving the asymmetric oxidation of a pro-chiral sulphide in chloroform using a chiral titanium complex and a hydroperoxide oxidant, with the addition of a 4Å molecular sieve, to achieve high enantioselectivity and yield of the optically pure (-) or (+) enantiomer, which are more effective than their racemate in treating gastric acid-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current synthesis methods are used for preparing enantiomerically enriched benzimidazole compounds, then the production process is relatively simple, but the enantioselectivity and yield are low
Solution Approach 1:
A chiral titanium complex is introduced as an intermediary catalyst to mediate the asymmetric oxidation reaction. The complex acts as a mediator that transfers chirality from the chiral ligand to the product, achieving high enantioselectivity (up to 99% ee) while maintaining process feasibility through catalytic action.
Solution Approach 2:
The reaction parameters are optimized including using chloroform as solvent, controlling temperature between -78°C to room temperature, and adjusting the stoichiometry of reactants. These parameter changes enable high enantioselectivity and yield without requiring overly complex process conditions.
2Productivity
If current synthesis methods are used for preparing enantiomerically enriched benzimidazole compounds, then the process conditions are relatively simple, but the yield is poor
Solution Approach 1:
The chiral titanium complex serves as a catalytic intermediary that not only controls stereoselectivity but also enhances reaction efficiency and yield. The catalyst activates the oxidant and facilitates the asymmetric oxidation, achieving up to 90% yield with enantiomeric excess up to 99%.
Solution Approach 2:
A hydroperoxide oxidant is employed to accelerate the oxidation of the sulphide to sulphoxide. The strong oxidizing power of hydroperoxide, combined with the chiral titanium complex catalyst, enables high-yield production of the optically active sulphoxide compound.
3Reliability
If racemic compounds are used for treating gastric acid-related disorders, then the treatment cost is lower, but the efficacy is reduced compared to optically pure compounds
Solution Approach 1:
The invention produces optically pure (asymmetric) compounds through asymmetric oxidation using a chiral titanium complex. The asymmetric structure of the pure enantiomer provides superior pharmacological activity and reliability in treating gastric acid-related disorders compared to racemic mixtures, justifying the enhanced manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in optically pure compounds with enantiomeric excesses up to 99%, demonstrating enhanced efficacy in treating gastric ulcers, duodenal ulcers, GORD, and Zollinger-Ellison syndrome by effectively inhibiting gastric acid secretion.
Implementation Method 1
asymmetric oxidation of a pro-chiral sulphide in chloroform using a chiral titanium complex and a hydroperoxide oxidant
Implementation Method 2
using a chiral titanium complex
Implementation Method 3
with the addition of a 4Å molecular sieve
Data Source
AI summary
Disclosed are an optically pure compound having formula (I), its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided. Formula (I).